# Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
Canonical URL: https://biopharmsignal.com/news/LSTA/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent
Ticker: LSTA
Company: Lisata Therapeutics
Source: Lisata Therapeutics
Published: 2025-11-04 21:00 EST
Original Source URL: https://ir.lisata.com
## Summary

Data from Catalent’s preclinical studies evaluating certepetide as a SMARTag® ADC payload showed both improved tumor selective penetration and efficacy BASKING RIDGE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage

## Article Body
Data from Catalent’s preclinical studies evaluating certepetide as a SMARTag® ADC payload showed both improved tumor selective penetration and efficacy BASKING RIDGE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage
## Recent Company News
- 2026-03-06 23:15 EST — [Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.](https://biopharmsignal.com/news/LSTA/lisata-therapeutics-enters-into-definitive-agreement-to-be-acquired-by-kuva-labs-inc) — Source: Lisata Therapeutics
- 2026-01-27 13:00 EST — [Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide](https://biopharmsignal.com/news/LSTA/lisata-therapeutics-announces-mutual-termination-of-license-agreement-with-qilu-pharmaceutical-for-certepetide) — Source: Lisata Therapeutics
- 2026-01-21 12:00 EST — [Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer](https://biopharmsignal.com/news/LSTA/lisata-therapeutics-enters-into-term-sheet-to-be-acquired-by-kuva-labs-for-4-00-per-share-in-an-all-cash-tender-offer) — Source: Lisata Therapeutics
- 2025-11-06 21:05 EST — [Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update](https://biopharmsignal.com/news/LSTA/lisata-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business-update) — Source: Lisata Therapeutics
- 2025-11-06 13:00 EST — [Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’](https://biopharmsignal.com/news/LSTA/lisata-therapeutics-wins-2025-biotech-breakthrough-award-for-overall-biopharma-solution-of-the-year) — Source: Lisata Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)